Phase Ib Study Assessing Different Sequencing Regimens of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients Who Have Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
Phase of Trial: Phase I
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Atezolizumab (Primary) ; Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 10 Jul 2018 Planned End Date changed from 1 Jan 2019 to 1 Jan 2020.
- 10 Jul 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.
- 02 May 2017 Status changed from not yet recruiting to recruiting.